The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)

Part of paid clinical trials in Cities in California, California.

Sponsor
AstraZeneca
Study ID
NCT00108823
Phase
PHASE3
Status
Completed

Conditions

  • Chronic Obstructive Pulmonary Disease, COPD

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this trial is to study the effects of roflumilast on lung function parameters indicative of hyperinflation in patients with COPD.

Key Dates

Start date
Oct 31, 2004
Status verified
Sep 2016

Study Design

Enrollment
550 participants
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

Lung function parameters indicative of hyperinflation in patients with COPD

Locations (10)

FacilityCityStateZIPSite coordinators
ALTANA PharmaCities in CaliforniaCalifornia--
ALTANA PharmaCities in ColoradoColorado--
ALTANA PharmaCities in FloridaFlorida--
ALTANA PharmaCities in MissouriMissouri--
ALTANA PharmaCities in New MexicoNew Mexico--
ALTANA PharmaCities in New YorkNew York--
ALTANA PharmaCities in OregeonOregon--
ALTANA PharmaCities in South CarolinaSouth Carolina--
ALTANA PharmaCities in TexasTexas--
ALTANA PharmaCities in WashingtonWashington--

Find similar trials in Cities in California, CA

By research site
ALTANA Pharma· Cities in California, CAALTANA Pharma· Cities in Colorado, COALTANA Pharma· Cities in Florida, FLALTANA Pharma· Cities in Missouri, MOALTANA Pharma· Cities in New Mexico, NMALTANA Pharma· Cities in New York, NY